Law360, New York (September 25, 2009) -- The U.S. Court of Appeals for the Federal Circuit has upheld a lower court's ruling that AstraZeneca Pharmaceuticals LP did not engage in inequitable conduct when seeking a patent for its antipsychotic drug Seroquel, rejecting a challenge by generics makers Sandoz Inc. and Teva Pharmaceutical Industries Ltd.
In a ruling Friday, the appeals court upheld the grant of summary judgment to AstraZeneca by the of the U.S. District Court for the District of New Jersey. The lower...
